Work

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.18_suppl.lba9008

Authors: Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Susan Doleman, Yining Ye, Ari M. Vanderwalde, Robert Coffin, Howard Kaufman

Institutions: Huntsman Cancer Institute, University of North Carolina at Chapel Hill, Mary Crowley Cancer Research Center, University of Louisville, Emory University, Northern California Melanoma Center, Vanderbilt University Medical Center, Amgen (United States), Rush University Medical Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4244325804

Cites:

Cited by: 86

Related to: 10